Learn

This track will focus on recent innovations across the assay development and screening discipline, including the adoption of novel technologies and the implementation of effective, innovative screening campaigns and hit triage strategies. Attendees will learn about the development of robust, physiologically relevant biochemical, biophysical and cellular assays that are crucial for identifying novel targets and active ligands that engage their targets directly. There will be an emphasis on recent case studies where cutting-edge assay approaches have increased the success rates of screening for target discovery and lead identification campaigns. Additional attention will be paid to emerging screening efforts that have been coupled with next-generation therapeutic modalities and novel mechanisms of action to broaden the scope of target classes that can be drugged. Taken together, the overall track will highlight advances in the fields of assay development and screening that enhance efforts to identify, validate and characterize novel targets and potential leads molecules.

View Presentations

This track focuses on the innovative use of biological or chemistry applications, tools, technologies and techniques as they pertain to automated high-throughput screening, the advancement of laboratory processes or improvement of the quality and impact of experimental laboratory data. Emphasis is placed on advancements in chemically and biologically relevant technologies using engineering, analytical, informatics, and application to cutting edge automation-assisted research.

View Presentations

Attendees will learn from industry and academic leaders about new cellular technologies and their application in the understanding of normal physiology and disease, and in the generation of disease-relevant models for drug discovery and pre-clinical development. The track will cover models used for illuminating functional genomics and for pharmacology, ADME or toxicity outcomes. The technologies covered will include the generation and use of patient-derived models, iPSC models, complex co-cultures, organoids, organ-on-chips, and microphysiologic models. The track will also include cellular therapeutics and cell technologies to support biologics and gene therapy approaches.

View Presentations

Data science and AI have become common topics in life sciences at an exponential rate. A decade ago, companies were infrequently knowledgeable about the applications for these technologies, whereas today we see large organizations focusing on data digitization strategies, small organizations with hugely aspirational computational goals, and even some drug discovery companies launching with a computational science platform as their primary differentiator. The conversation has decidedly shifted from "what if" to "when", and the competition is fierce - both to set your organization apart and to get the right expertise to wield the technology. This track will focus on how data science helps organize and make sense of life science data, and in return, how companies and groups can best support data science teams through literacy goals and pipelines for growth and hiring. Emphasis will be placed on stories from groups that leverage data science and AI in new and novel ways to both show successes and lessons for others to learn from, and to bring up new moonshot ideas that help our field continue to grow and nurture itself.

View Presentations

Micro- and nano-technologies have leveraged their unique physics and their ability to interact with biological systems at matched length scales to advance novel insights into human health. With micro- and nanotechnologies now being scaled via automation, integrated with optical systems and assembled into structured materials, their impact to biological research and medical science is now larger than ever. This track will highlight recent advances in multi-omic, high-content platforms that enable insights at subcellular lengthscales and in the fabrication and application of novel micro- and nanomaterials.

View Presentations

Our disease understanding has revealed targets that are challenging to treat with typical inhibitor approaches. The next generation of therapeutics needs novel drug-target strategies that transcend transcend traditional chemical space. This track will provide drug discovery scientists with the latest information on protein degraders and stablizers, nucleic acid-targeting molecules, nucleic acid therapeutics and other emerging modalities.

View Presentations

Omics technologies have become an integral part of science and medicine, from cutting edge discovery of biomarkers to a personalized approach to health and wellness including early detection and treatment of cancer. In this session we explore four main avenues where omics approaches have revolutionized cancer research, personal health and wellness, single cell and spatial technologies and drug discovery and therapy.

View Presentations

The Precision Medicine & Diagnostics track focuses on approaches that aim to provide translatable insight into disease biology. This includes cellular, molecular, biochemical, engineering and bioinformatic strategies in diagnostics, screening and translational medicine. The session will emphasize the application of state-of-the-art, quantitative, high-throughput and high-resolution approaches to both cellular models and complex tissues. These strategies enable multiparametric computational analyses to reveal the complex interplay of genetics, cell types and drugs to advance precision medicine. Topics include improvements in stem cell-based disease modelling, bioengineering, molecular and cellular assays, bioinformatic and imaging approaches.

View Presentations